ReviewNature reviews. Disease primers2024
Tumour lysis syndrome.
Review in Nature reviews. Disease primers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Tumor Lysis Syndrome in Colorectal Cancer-A Systematic Review of Literature.Journal of gastrointestinal cancer · 2026Pooled it
- Trial
- Pediatric tumor lysis syndrome: the nephrologist's role in prevention and management.Pediatric nephrology (Berlin, Germany) · 2026Review
- The microbiome regulates host metabolic health and diseases through microbial enzymes.Nature reviews. Gastroenterology & hepatology · 2026Review
- Macrophages sense and follow physiologically relevant KCell communication and signaling : CCS · 2026Article
- Tumor lysis syndrome in a pediatric patient with Burkitt lymphoma following emergence from general anesthesia: a case report.Journal of medical case reports · 2026Article
- Serum uric acid and its metabolism-a vital factor in the inflammatory transformation of cancer.Journal of advanced research · 2026Review
- Life-Threatening Acute Tumor Lysis Syndrome With Multiorgan Failure Following First Cycle of Bendamustine-Rituximab in Chronic Lymphocytic Leukemia: A Case Report and Brief Review.Clinical case reports · 2026Article
- Continuous hemodiafiltration during chemotherapy for acute kidney injury in spontaneous tumor lysis syndrome due to high-grade B-cell lymphoma: a case report.CEN case reports · 2026Article
- Therapeutic potential of traditional Chinese medicine for hyperuricemia: mechanistic insights and clinical prospects.Frontiers in pharmacology · 2026Review
- Real-world pharmacovigilance analysis of pralatrexate using the FDA adverse event reporting system database.Frontiers in pharmacology · 2026Article
- Tumor lysis syndrome in children with hematological malignancies: a nephrology perspective in resource-limited settings.Frontiers in oncology · 2026Article
- Article
- Real-world safety of first-line enfortumab vedotin plus pembrolizumab in advanced urothelial carcinoma: evidence from VigiBase and FAERS.Frontiers in immunology · 2026Article
- Cell Surface Ion-Seq: Potassium Ion Monitoring in the Colorectal Cancer Cellular Microenvironment Based on Split G‑quadruplex Probe.ACS central science · 2025Article
- Folic acid ameliorates placental structure and function in fetal growth restriction via epigenetic modifications.Clinical epigenetics · 2025Article
- The Use of Single Dose of Rasburicase for the Prophylaxis and Treatment of Tumor Lysis Syndrome in Pediatric Patients: A Narrative Review.Hematology reports · 2025Review
- Rasburicase vs. allopurinol: mortality in hematological malignancies post anti-hyperuricemic therapy - real-world study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Management of acute kidney injury in tumor lysis syndrome: a narrative review.Internal and emergency medicine · 2025Review
- Spontaneous tumor lysis syndrome following liver biopsy: a case report and literature review.Frontiers in oncology · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumour lysis syndrome (TLS) represents a critical oncological emergency characterized by extensive tumour cell breakdown, leading to the swift release of intracellular contents into the systemic circulation, outpacing homeostatic mechanisms. This process results in hyperuricaemia (a by-product of intracellular DNA release), hyperkalaemia, hyperphosphataemia, hypocalcaemia and the accumulation of xanthine. These electrolyte and metabolic imbalances pose a significant risk of acute kidney injury, cardiac arrhythmias, seizures, multiorgan failure and, rarely, death. While TLS can occur spontaneously, it usually arises shortly after the initiation of effective treatment, particularly in patients with a large cancer cell mass (defined as ≥500 g or ≥300 g/m
Indexed as
Identifiers
39174582What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.